Clinical trials
Small Cell Lung Cancer clinical trials
Below are recruiting small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,491 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Huntsville, AlabamaAges 18 years+ - NCT06897046RecruitingPhase 2
Study of Iparomlimab and Tuvonralimab for resectable lung cancer
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
BeijingAges 18 years+ - NCT06896422RecruitingPhase 1
Testing glutathione with immunotherapy and chemo for lung cancer
This trial tests adding a supplement called glutathione to the usual immunotherapy (anti-PD-1) plus chemotherapy for advanced non-small cell lung cancer that has stopped responding to first treatment. It aims to see if this combination works better at shrinking tumors.
Zhengzhou, HenanAges 18 years+ - NCT05989542RecruitingPhase 3
Study of vebreltinib for MET-mutated lung cancer
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06885424Enrolling by invitation
Long-term follow-up for A2 Bio gene therapy patients
This study follows up with people who previously received a gene therapy product from A2 Biotherapeutics in an earlier trial. The goal is to monitor their health over time and check for any long-term effects.
Gilbert, ArizonaAges 18 years+ - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06878274RecruitingPhase 2
Radiation after chemo-immunotherapy and surgery for stage III lung cancer
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
Montreal, QuebecAges 18 years+ - NCT06876675Enrolling by invitation
Lorlatinib and high cholesterol in ALK+ lung cancer
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
BeijingAges 18–80 - NCT06877299RecruitingPhase 2
Combination Therapy for Stage IIA-IIIB Lung Cancer
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
Chengdu, ChinaAges 18–75 - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT06868732RecruitingPhase 1
A new drug combination for advanced non-small cell lung cancer
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06873555RecruitingPhase 1/Phase 2
Study of a new drug for ovarian cancer and other advanced solid tumors
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT06868849RecruitingPhase 1/Phase 2
Study of JMT203 for Cancer-Related Weight Loss
This trial tests a new drug called JMT203 for people with cancer-related weight loss (cachexia). It aims to see if the drug can help prevent or reverse weight loss in patients with certain solid tumors who are also receiving or have recently completed anti-cancer therapy.
ZhejiangAges 18 years+ - NCT03093688RecruitingPhase 1/Phase 2
Testing an immune-cell infusion for advanced solid tumors
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Oxnard, CaliforniaAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06866717Recruiting
Exercise before lung cancer surgery
This trial tests whether doing exercise training before lung cancer surgery can help you recover better. It is for people with low fitness levels who live with another adult at home.
RouenAges 18 years+ - NCT06846736Enrolling by invitation
Predicting ALK cancer treatment outcomes using digital pathology
This study uses a computer to analyze digital images of tumor tissue from people with a certain type of lung cancer (ALK-positive non-small cell lung cancer). It aims to see if the computer can predict how well newer-generation ALK inhibitors work in these patients.
Ramat GanAges 18 years+ - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung cancer?
- Yes. Clin2 currently lists 1,491 recruiting small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.